Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.67 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.65 |
| ▸ | OSBP | P22059 | 3/20 | 0.61 |
| ▸ | USP2 | O75604 | 2/20 | 0.61 |
| ▸ | RORC | P51449 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.61 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.61 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.55 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | GBA1 | P04062 | 2/20 | 0.53 |
| ▸ | UGCG | Q16739 | 2/20 | 0.53 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.53 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.53 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28354580 | 1.00 | POLA1 (0.67) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL1173285 | 1.00 | POLA1 (0.67) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL1296893 | 0.92 | POLA1 (0.75) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL19991732 | 0.90 | POLA1 (0.67) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL2979168 | 0.89 | POLA1 (0.69) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL1296890 | 0.89 | POLA1 (0.73) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL2979167 | 0.89 | POLA1 (0.69) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL4437346 | 0.89 | POLA1 (0.73) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL9186858 | 0.89 | POLA1 (0.69) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL1296888 | 0.89 | POLA1 (0.73) | POLA1CYP46A1OSBPUSP2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009079546-A1 | CHOLESTERIC LIQUID CRYSTAL COLORING COMPOSITIONS AND ARTICLES PRODUCED THEREFROM | AVON PRODUCTS, INC. (US) | 2009-06-25 | — | — | WO | claimed |
| US-20220162581-A1 | Solution Stable Enzyme Composition | AB ENZYMES FINLAND OY (FI) | 2022-05-26 | — | — | US | disclosed |
| EP-3953459-A1 | SOLUTION STABLE ENZYME COMPOSITION | AB Enzymes Oy (FI) | 2022-02-16 | — | — | EP | disclosed |
| WO-2020208296-A1 | SOLUTION STABLE ENZYME COMPOSITION | AB ENZYMES OY (FI) | 2020-10-15 | — | — | WO | disclosed |
| EP-3722418-A1 | SOLUTION STABLE ENZYME COMPOSITION | AB Enzymes Oy (FI) | 2020-10-14 | — | — | EP | disclosed |
| EP-1256336-B1 | Two-phase gel composition | PENRECO (US) | 2016-10-19 | — | — | EP | disclosed |
| US-9339446-B2 | Gel composition | CALUMET PENRECO, LLC (US) | 2016-05-17 | — | — | US | disclosed |
| US-20110045983-A1 | Gel composition | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2011-02-24 | — | — | US | disclosed |
| US-20090232753-A1 | Gel compositions | HEALY LIN LU | 2009-09-17 | — | — | US | disclosed |
| WO-2009079546-A1 | CHOLESTERIC LIQUID CRYSTAL COLORING COMPOSITIONS AND ARTICLES PRODUCED THEREFROM | AVON PRODUCTS, INC. (US) | 2009-06-25 | — | — | WO | disclosed |
| EP-1141111-B1 | GEL COMPOSITIONS | PENRECO (US) | 2005-08-03 | — | — | EP | disclosed |
| US-6881776-B2 | Gel compositions | PENRECO (US) | 2005-04-19 | — | — | US | disclosed |
| US-20050004274-A1 | Gel compositions | HEALY LIN LU (US) | 2005-01-06 | — | — | US | disclosed |
| EP-1256336-A2 | Two-phase gel composition | Penreco (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20020055562-A1 | Gel compositions | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2002-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110045983-A1 | Gel composition | PGR, COPE, PTGER1 | POLA1 1495/4885CYP46A1 499/4885OSBP 810/4885 |
| US-20090232753-A1 | Gel compositions | PGR, COPE, PTGER1 | POLA1 1637/4885CYP46A1 579/4885OSBP 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.